tRNA Modifying Enzymes, NSUN2 and METTL1, Determine Sensitivity to 5-Fluorouracil in HeLa Cells

English version České info

The cellular mechanisms for sensing and responding to stress on nucleic acid metabolism or to genotoxic stress are the fundamental and ancient evolutionary biological activities with conserved and diverse biological functions. In yeast, hypomodified mature tRNA species are rapidly decayed under heat stress by the RTD pathway. Yet, it has been shown that tRNA-specific methyltransferases Trm4 and Trm8 protect from tRNA decay. 5-FU, a pyrimidine analog used for cancer treatment, is generally known to act as a thymidylate synthase inhibitor although other ways for the mechanisms of action are suggested. We studied NSUN2 and METTL1, the human orthologs of Trm4 and Trm8 in yeast, and demonstrated that these RTD-related tRNA modifying enzymes are involved in 5-FU sensitivity in cervical cancer HeLa cells. We conclude that the evolutionarily conserved regulation of tRNA modifications is a potential mechanism of chemotherapy resistance in cancer cells.

Vyšlo v časopise: tRNA Modifying Enzymes, NSUN2 and METTL1, Determine Sensitivity to 5-Fluorouracil in HeLa Cells. PLoS Genet 10(9): e32767. doi:10.1371/journal.pgen.1004639
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004639

Souhrn

Zdroje

1. LongleyDB, HarkinDP, JohnstonPG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330–338.

2. BenzC, TillisT, TattelmanE, CadmanE (1982) Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42: 2081–2086.

3. BertinoJR, MiniE, FernandesDJ (1983) Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin Oncol 10: 2–5.

4. BonnefoiH, SmithIE, O'BrienME, SeymourMT, PowlesTJ, et al. (1996) Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 73: 391–396.

5. GrecoFA, FiglinR, YorkM, EinhornL, SchilskyR, et al. (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14: 2674–2681.

6. JonesDVJr, WinnRJ, BrownBW, LevyLB, PughRP, et al. (1995) Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. Cancer 76: 1709–1714.

7. MarsoniS (1995) Fluorouracil and folinic acid in colon cancer. IMPACT Investigators. Lancet 345: 1582–1583.

8. NadalJC, Van GroeningenCJ, PinedoHM, PetersGJ (1988) In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42: 387–393.

9. WolmarkN, BryantJ, SmithR, GremJ, AllegraC, et al. (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90: 1810–1816.

10. HungSW, ModyHR, GovindarajanR (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 320: 138–149.

11. ShiS, YaoW, XuJ, LongJ, LiuC, et al. (2012) Combinational therapy: new hope for pancreatic cancer? Cancer Lett 317: 127–135.

12. de la Cruz-MorcilloMA, ValeroML, Callejas-ValeraJL, Arias-GonzalezL, Melgar-RojasP, et al. (2012) P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene 31: 1073–1085.

13. CartlidgeRA, KnebelA, PeggieM, AlexandrovA, PhizickyEM, et al. (2005) The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells. EMBO J 24: 1696–1705.

14. FryeM, DragoniI, ChinSF, SpiteriI, KurowskiA, et al. (2010) Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. Cancer Lett 289: 71–80.

15. OkamotoM, HirataS, SatoS, KogaS, FujiiM, et al. (2012) Frequent increased gene copy number and high protein expression of tRNA (cytosine-5-)-methyltransferase (NSUN2) in human cancers. DNA Cell Biol 31: 660–671.

16. WikmanH, NymarkP, VayrynenA, JarmalaiteS, KallioniemiA, et al. (2005) CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42: 193–199.

17. Sakita-SutoS, KandaA, SuzukiF, SatoS, TakataT, et al. (2007) Aurora-B regulates RNA methyltransferase NSUN2. Mol Biol Cell 18: 1107–1117.

18. MotorinY, GrosjeanH (1999) Multisite-specific tRNA:m5C-methyltransferase (Trm4) in yeast Saccharomyces cerevisiae: identification of the gene and substrate specificity of the enzyme. RNA 5: 1105–1118.

19. WuP, BrockenbroughJS, PaddyMR, ArisJP (1998) NCL1, a novel gene for a non-essential nuclear protein in Saccharomyces cerevisiae. Gene 220: 109–117.

20. AlexandrovA, MartzenMR, PhizickyEM (2002) Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA 8: 1253–1266.

21. AlexandrovA, ChernyakovI, GuW, HileySL, HughesTR, et al. (2006) Rapid tRNA decay can result from lack of nonessential modifications. Mol Cell 21: 87–96.

22. ChernyakovI, WhippleJM, KotelawalaL, GrayhackEJ, PhizickyEM (2008) Degradation of several hypomodified mature tRNA species in Saccharomyces cerevisiae is mediated by Met22 and the 5′-3′ exonucleases Rat1 and Xrn1. Genes Dev 22: 1369–1380.

23. WhippleJM, LaneEA, ChernyakovI, D'SilvaS, PhizickyEM (2011) The yeast rapid tRNA decay pathway primarily monitors the structural integrity of the acceptor and T-stems of mature tRNA. Genes Dev 25: 1173–1184.

24. BahrA, HankelnT, FiedlerT, HegemannJ, SchmidtER (1999) Molecular analysis of METTL1, a novel human methyltransferase-like gene with a high degree of phylogenetic conservation. Genomics 57: 424–428.

25. GustavssonM, RonneH (2008) Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast. RNA 14: 666–674.

26. FryeM, WattFM (2006) The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr Biol 16: 971–981.

27. BlancoS, KurowskiA, NicholsJ, WattFM, BenitahSA, et al. (2011) The RNA-methyltransferase Misu (NSun2) poises epidermal stem cells to differentiate. PLoS Genet 7: e1002403.

28. KuchinoY, BorekE (1976) Changes in transfer RNA's in human malignant trophoblastic cells (BeWo line). Cancer Res 36: 2932–2936.

29. Pavon-EternodM, GomesS, GeslainR, DaiQ, RosnerMR, et al. (2009) tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res 37: 7268–7280.

30. AuxilienS, GuerineauV, Szweykowska-KulinskaZ, Golinelli-PimpaneauB (2012) The human tRNA m (5) C methyltransferase Misu is multisite-specific. RNA Biol 9: 1331–1338.

31. SquiresJE, PatelHR, NouschM, SibbrittT, HumphreysDT, et al. (2012) Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic Acids Res 40: 5023–5033.

32. KhoddamiV, CairnsBR (2013) Identification of direct targets and modified bases of RNA cytosine methyltransferases. Nat Biotechnol 31: 458–464.

33. HussainS, SajiniAA, BlancoS, DietmannS, LombardP, et al. (2013) NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. Cell Rep 4: 255–261.

34. ZhangX, LiuZ, YiJ, TangH, XingJ, et al. (2012) The tRNA methyltransferase NSun2 stabilizes p16INK(4) mRNA by methylating the 3′-untranslated region of p16. Nat Commun 3: 712.

35. MartinezFJ, LeeJH, LeeJE, BlancoS, NickersonE, et al. (2012) Whole exome sequencing identifies a splicing mutation in NSUN2 as a cause of a Dubowitz-like syndrome. J Med Genet 49: 380–385.

36. KhanMA, RafiqMA, NoorA, HussainS, FloresJV, et al. (2012) Mutation in NSUN2, which encodes an RNA methyltransferase, causes autosomal-recessive intellectual disability. Am J Hum Genet 90: 856–863.

37. Abbasi-MohebL, MertelS, GonsiorM, Nouri-VahidL, KahriziK, et al. (2012) Mutations in NSUN2 cause autosomal-recessive intellectual disability. Am J Hum Genet 90: 847–855.

38. HussainS, BenaventeSB, NascimentoE, DragoniI, KurowskiA, et al. (2009) The nucleolar RNA methyltransferase Misu (NSun2) is required for mitotic spindle stability. J Cell Biol 186: 27–40.

39. TownsWL, BegleyTJ (2012) Transfer RNA methytransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health. DNA Cell Biol 31: 434–454.

40. WatanabeK, MiyagawaR, TomikawaC, MizunoR, TakahashiA, et al. (2013) Degradation of initiator tRNAMet by Xrn1/2 via its accumulation in the nucleus of heat-treated HeLa cells. Nucleic Acids Res 41: 4671–4685.

41. RuggeroD, PandolfiPP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3: 179–192.

42. PandolfiPP (2004) Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 23: 3134–3137.

43. Lazaris-KaratzasA, MontineKS, SonenbergN (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345: 544–547.

44. TatsukaM, MitsuiH, WadaM, NagataA, NojimaH, et al. (1992) Elongation factor-1 alpha gene determines susceptibility to transformation. Nature 359: 333–336.

45. BorekE, KerrSJ (1972) Atypical transfer RNA's and their origin in neoplastic cells. Adv Cancer Res 15: 163–190.

46. Pavon-EternodM, GomesS, RosnerMR, PanT (2013) Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells. RNA 19: 461–466.

47. SuzukiF, HorikawaM (1973) A replica plating method of cultured mammalian cells. Methods Cell Biol 6: 127–142.

48. Kakunaga T (1981) Approaches toward developing a human transformation assay system. In: Myron AM, Nawin CM, editors. Mammalian Cell Transformation by Chemical Carcinogens. Washington, DC, U.S.A.: Senate Press. pp. 355–382.

49. SuzukiF, SuzukiK, NikaidoO (1984) An improved soft agar method for determining neoplastic transformation in vitro. J Tissue Cult Methods 8: 109–113.

50. FrankenNA, RodermondHM, StapJ, HavemanJ, van BreeC (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315–2319.

51. TatsukaM, SatoS, KitajimaS, SutoS, KawaiH, et al. (2005) Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 24: 1122–1127.

52. KandaA, KawaiH, SutoS, KitajimaS, SatoS, et al. (2005) Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 24: 7266–7272.